The UPR-oxidative stress nexus in diabetes and obesity: Exploring innovative therapeutic approaches for metabolic control

dc.contributor.authorAkanbi, Clinton Ayodeji
dc.contributor.authorOjo, Oluwafemi Adeleke
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id499519668
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/499519668
dc.date.accessioned2026-01-21T14:33:49Z
dc.date.available2026-01-21T14:33:49Z
dc.description.abstractMaintaining cellular protein homeostasis requires the endoplasmic reticulum (ER); however, the unfolded protein response (UPR) can be triggered by the accumulation of misfolded proteins, which can cause ER stress. The goal of the UPR is to bring the body back into balance. Nevertheless, long-term ER stress can cause β-cell dysfunction and apoptosis, which greatly exacerbates metabolic diseases such as diabetes and obesity. ER stress worsens insulin resistance and reduces glucose metabolism in pancreatic β-cells. Moreover, the ER is further damaged by oxidative stress, which is defined by an excess of reactive oxygen species (ROS), which prolongs metabolic dysfunction. This review delves into the molecular mechanisms that underlie ER stress, its consequences for diabetes and obesity, and possible treatment approaches. We discuss interventions to mitigate ER stress, including chemical chaperones, UPR modulators, and dietary strategies. Current pharmacological approaches, such as chemical chaperones and UPR modulators, have demonstrated efficacy in reducing ER stress, but they often present challenges, including inconsistent treatment responses and off-target effects. Antioxidant-rich dietary strategies, while promising for long-term management, require further validation to ensure their safety and effectiveness. Additionally, advances in CRISPR–Cas9 gene-editing technology provide new opportunities for addressing genetic defects associated with these disorders. These findings emphasize the need for integrated therapies that address both oxidative and ER stress to effectively mitigate metabolic dysfunction.
dc.embargo.lift2026-07-20
dc.identifier.jour-issn2451-8476
dc.identifier.olddbid213405
dc.identifier.oldhandle10024/196423
dc.identifier.urihttps://www.utupub.fi/handle/11111/55304
dc.identifier.urlhttps://doi.org/10.1016/j.obmed.2025.100634
dc.identifier.urnURN:NBN:fi-fe202601215540
dc.language.isoen
dc.okm.affiliatedauthorOjo, Oluwafemi
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherElsevier BV
dc.publisher.countryNetherlandsen_GB
dc.publisher.countryAlankomaatfi_FI
dc.publisher.country-codeNL
dc.relation.articlenumber100634
dc.relation.doi10.1016/j.obmed.2025.100634
dc.relation.ispartofjournalObesity Medicine
dc.relation.volume57
dc.source.identifierhttps://www.utupub.fi/handle/10024/196423
dc.titleThe UPR-oxidative stress nexus in diabetes and obesity: Exploring innovative therapeutic approaches for metabolic control
dc.year.issued2025

Tiedostot